Vytrus BiotechXMAD:VYT -0.57%69 Return-on-Tangible-Equity is 59.01% as of Dec. 2025, which is 70% above its 10-year median of 34.76. GuruFocus rates XMAD:VYT with a GF Score™ of 69/100 and a GF Value™ of €5.55 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Vytrus Biotech ranks better than 96.25% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vytrus Biotech's annualized net income for the quarter that ended in Dec. 2025 was €2.91 Mil. Vytrus Biotech's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €4.93 Mil. Therefore, Vytrus Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 59.01%.
The historical rank and industry rank for Vytrus Biotech's Return-on-Tangible-Equity or its related term are showing as below:
XMAD:VYT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -15.02 Med: 34.76 Max: 67.6
Current: 66.44
During the past 8 years, Vytrus Biotech's highest Return-on-Tangible-Equity was 67.60%. The lowest was -15.02%. And the median was 34.76%.
XMAD:VYT's Return-on-Tangible-Equity is ranked better than 96.25% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs XMAD:VYT: 66.44
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vytrus Biotech Return-on-Tangible-Equity Related Terms
Vytrus Biotech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:VYT vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Vytrus Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 59.01% mean?
Vytrus Biotech (XMAD:VYT) has a Return-on-Tangible-Equity of 59.01% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vytrus Biotech and its competitors. This is 70% above median its historical median of 34.76. According to the industry distribution chart, Vytrus Biotech ranks #45 out of 1199 companies in the Biotechnology industry, placing it in the top 3.8%.
Is Vytrus Biotech's Return-on-Tangible-Equity too high?
Vytrus Biotech's current Return-on-Tangible-Equity of 59.01% is 70% above median its 10-year median of 34.76. Based on the distribution chart, Vytrus Biotech ranks #45 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #45 out of 1199 companies for Return-on-Tangible-Equity. This places Vytrus Biotech in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vytrus Biotech and its competitors. Vytrus Biotech's current Return-on-Tangible-Equity is 59.01%, which is 70% above median its own 10-year median of 34.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.55, compared to a current price of €17.40 — trading 213.5% above its estimated fair value. The current Return-on-Tangible-Equity is 59.01%, which is 70% above median its 10-year median of 34.76. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Return-on-Tangible-Equity is 59.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €17.40 is trading 213.5% above its estimated GF Value™ of €5.55.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
Return-on-Tangible-Equity: 59.01% (70% above median its 10-year median of 34.76)
GF Value™: €5.55 vs. price of €17.40 (213.5% above fair value)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score
Get the complete analysis for XMAD:VYT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
